Hepatology
Conference Coverage
Liver disease-related deaths rise during pandemic
“The increasing trend in mortality rates for ALD and NAFLD has been quite alarming, with disparities in age, race, and ethnicity.”
Conference Coverage
World falls short on HBV, HCV elimination targets
“As countries progress toward eliminating hepatitis B and C, we really need to do more to expand political will and financing of national...
News
COVID tied to spike in deaths in chronic liver disease with diabetes
“Our observations confirm that COVID-19 had a higher likelihood of impacting vulnerable populations with pre-existing chronic liver diseases and...
News
FDA okays terlipressin (Terlivaz) injection for hepatorenal syndrome
The synthetic vasopressin analog is an injectable medication indicated for patients with hepatorenal syndrome experiencing rapid deterioration of...
News
Pervasive ‘forever chemical’ linked to liver cancer
People can limit exposure by avoiding water contaminated with ‘forever chemicals’ or filtering it.
News
Neighborhood factors contribute to liver cancer disparities in Texas
HCC is the most common type of liver cancer in the United States, and Texas has the highest rate.
News
HCV reinfection uncommon among people who inject drugs
In a new study, most reinfections occurred within 24 weeks of completing treatment.
News
New update focuses on NAFLD in lean people
Lean individuals older than 40 with type 2 diabetes should be screened for NAFLD, urge experts.
News
Liver cancer risk persists after direct-acting antiviral treatment for HCV
“Even with that decline in risk up to 7 years after eradication of hepatitis C with direct-acting antivirals, the risk is still high enough to...
Conference Coverage
Finding HBV ‘cure’ may mean going ‘back to the drawing board’
Development of new HBV drugs looks more complicated than initially expected, and it’s time to refine and refocus goals, according to one...